Nakagawa K - Search Results

1

Effect of CYP3A5*3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy.

Seo T, Nakada N, Ueda N, Hagiwara T, Hashimoto N, Nakagawa K, Ishitsu T. Seo T, et al. Among authors: nakagawa k. Clin Pharmacol Ther. 2006 May;79(5):509-10. doi: 10.1016/j.clpt.2006.02.009. Clin Pharmacol Ther. 2006. PMID: 16678552 No abstract available.

2

ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.

Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K, Nakagawa K. Seo T, et al. Among authors: nakagawa k. Pharmacogenomics. 2006 Jun;7(4):551-61. doi: 10.2217/14622416.7.4.551. Pharmacogenomics. 2006. PMID: 16753003

3

Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.

Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Abe T, et al. Among authors: nakagawa k, nakagawa t. Br J Clin Pharmacol. 2008 Aug;66(2):304-7. doi: 10.1111/j.1365-2125.2008.03203.x. Epub 2008 Apr 11. Br J Clin Pharmacol. 2008. PMID: 18489610 Free PMC article.

4

Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.

Goto S, Seo T, Murata T, Nakada N, Ueda N, Ishitsu T, Nakagawa K. Goto S, et al. Among authors: nakagawa k. Ther Drug Monit. 2007 Feb;29(1):118-21. doi: 10.1097/FTD.0b013e318030def0. Ther Drug Monit. 2007. PMID: 17304159

5

Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity.

Ueda K, Ishitsu T, Seo T, Ueda N, Murata T, Hori M, Nakagawa K. Ueda K, et al. Among authors: nakagawa k. Pharmacogenomics. 2007 May;8(5):435-42. doi: 10.2217/14622416.8.5.435. Pharmacogenomics. 2007. PMID: 17465707

6

Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.

Goto S, Seo T, Hagiwara T, Ueda K, Yamauchi T, Nagata S, Ando Y, Ishitsu T, Nakagawa K. Goto S, et al. Among authors: nakagawa k. J Pharm Pharmacol. 2008 Feb;60(2):267-72. doi: 10.1211/jpp.60.2.0017. J Pharm Pharmacol. 2008. PMID: 18237476 Clinical Trial.

7

ABCC2 haplotype is not associated with drug-resistant epilepsy.

Seo T, Ishitsu T, Oniki K, Abe T, Shuto T, Nakagawa K. Seo T, et al. Among authors: nakagawa k. J Pharm Pharmacol. 2008 May;60(5):631-5. doi: 10.1211/jpp.60.5.0009. J Pharm Pharmacol. 2008. PMID: 18416940

8

Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy.

Saruwatari J, Ogusu N, Shimomasuda M, Nakashima H, Seo T, Tanikawa K, Tsuda Y, Nishimura M, Nagata R, Yasui-Furukori N, Kaneko S, Ishitsu T, Nakagawa K. Saruwatari J, et al. Among authors: nakagawa k. Ther Drug Monit. 2014 Jun;36(3):302-9. doi: 10.1097/FTD.0000000000000015. Ther Drug Monit. 2014. PMID: 24345815

9

Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy.

Takata K, Saruwatari J, Nakada N, Nakagawa M, Fukuda K, Tanaka F, Takenaka S, Mihara S, Marubayashi T, Nakagawa K. Takata K, et al. Among authors: nakagawa k, nakagawa m. Eur J Clin Pharmacol. 2006 Jan;62(1):23-8. doi: 10.1007/s00228-005-0057-z. Epub 2005 Dec 30. Eur J Clin Pharmacol. 2006. PMID: 16385402

10

Glutathione-S-transferase (GST) M1 null genotype and combined GSTM1 and GSTT1 null genotypes are risk factors for increased serum gamma-glutamyltransferase in valproic acid-treated patients.

Fukushima Y, Seo T, Hashimoto N, Higa Y, Ishitsu T, Nakagawa K. Fukushima Y, et al. Among authors: nakagawa k. Clin Chim Acta. 2008 Mar;389(1-2):98-102. doi: 10.1016/j.cca.2007.11.035. Epub 2007 Dec 7. Clin Chim Acta. 2008. PMID: 18155166

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,710 results

Search Page